| Janet Louise Olsen, MD | |
|
30 Prospect Ave, Hackensack, NJ 07601-1914 | |
| (201) 488-0066 | |
| (201) 488-6769 |
| Full Name | Janet Louise Olsen |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 40 Years |
| Location | 30 Prospect Ave, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114901584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MA05125100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Jersey Healthcare Specialists Pc | 2668385253 | 554 |
News Archive
"This prion," explains Lindquist, "has a capacity to hide and release genetic information throughout the entire genome that can contribute to new traits in a complex way."
Air pollution is classified as carcinogenic to humans given its association with lung cancer, but there is little evidence for its association with cancer at other body sites. In a new large-scale prospective study led by the Barcelona Institute of Global Health, an institution supported by the "la Caixa" Foundation, and the American Cancer Society, researchers observed an association between some air pollutants and mortality from kidney, bladder and colorectal cancer.
MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.
› Verified 5 days ago
| Entity Name | New Jersey Healthcare Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174585780 PECOS PAC ID: 2668385253 Enrollment ID: O20031110000555 |
News Archive
"This prion," explains Lindquist, "has a capacity to hide and release genetic information throughout the entire genome that can contribute to new traits in a complex way."
Air pollution is classified as carcinogenic to humans given its association with lung cancer, but there is little evidence for its association with cancer at other body sites. In a new large-scale prospective study led by the Barcelona Institute of Global Health, an institution supported by the "la Caixa" Foundation, and the American Cancer Society, researchers observed an association between some air pollutants and mortality from kidney, bladder and colorectal cancer.
MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janet Louise Olsen, MD Po Box 18914, Newark, NJ 07191-8914 Ph: (201) 488-0066 | Janet Louise Olsen, MD 30 Prospect Ave, Hackensack, NJ 07601-1914 Ph: (201) 488-0066 |
News Archive
"This prion," explains Lindquist, "has a capacity to hide and release genetic information throughout the entire genome that can contribute to new traits in a complex way."
Air pollution is classified as carcinogenic to humans given its association with lung cancer, but there is little evidence for its association with cancer at other body sites. In a new large-scale prospective study led by the Barcelona Institute of Global Health, an institution supported by the "la Caixa" Foundation, and the American Cancer Society, researchers observed an association between some air pollutants and mortality from kidney, bladder and colorectal cancer.
MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.
› Verified 5 days ago
Mr. Philip Ofosu Eck, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave Ste 2703, Hackensack, NJ 07601 Phone: 551-996-2419 Fax: 551-996-3962 | |
Ms. Somdatta Gupta, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 973-216-7796 | |
Michael E Cullen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-488-0066 Fax: 201-488-6769 | |
William P Brotherton, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 140 Prospect Ave, Suite 8, Hackensack, NJ 07601 Phone: 201-488-0066 Fax: 201-488-6769 | |
Steven Alan Topfer, DO Anesthesiology Medicare: Medicare Enrolled Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-488-0066 Fax: 201-488-6769 | |
Stephen M Weitzman, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 100 Prospect Ave, 4f, Hackensack, NJ 07601 Phone: 201-487-8557 | |
Angela Catherine Lee, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 30 Prospect Ave Ste 2703, Hackensack, NJ 07601 Phone: 551-996-2419 |